Acute phase responses and cytokine secretion in chronic fatigue syndrome

被引:67
作者
Cannon, JG
Angel, JB
Ball, RW
Abad, LW
Fagioli, L
Komaroff, AL
机构
[1] Penn State Univ, Noll Physiol Res Ctr, University Pk, PA 16802 USA
[2] New England Med Ctr, Dept Med, Boston, MA 02111 USA
[3] Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA
[4] Tufts Univ, USDA, Jean Mayer Human Nutr Res Ctr Aging, Boston, MA 02111 USA
关键词
chronic fatigue syndrome; acute phase responses;
D O I
10.1023/A:1020558917955
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This study addresses the hypothesis that clinical manifestations of chronic fatigue syndrome (CFS) are due in part to abnormal production of or sensitivity to cytokines such as interleukin-1 beta (IL-1 beta) and IL-6 under basal conditions or in response to st particular physical stress: 15 min of exercise consisting of stepping up and down on a platform adjusted to the height of the patella. The study involved 10 CFS patients and 11 age-, sex-, and activity-matched controls: of these, 6 patients and 4 controls were tested in both the follicular and the luteal phases of the menstrual cycle, and the remainder were tested in only one phase, for a total of 31 experimental sessions. Prior to exercise, plasma concentrations of the acute phase reactant alpha(2)-macroglobulin were 29% higher in CFS patients (P < 0.008) compared to controls. Secretion of IL-6 was generally higher for CFS patients (similar to 38%), however, this difference was statistically significant only if all values over a 3-day period were analyzed by repeated-measures ANOVA(P = 0.035). IL-6 secretion correlated with plasma alpha(2)-macroglobulin in control subjects at rest (R = 0.767, P = 0.001). Immediately after exercise, the CFS patients reported greater ratings of perceived exertion (P = 0.027) compared to the healthy control subjects. Ratings of perceived exertion correlated with IL-1 beta secretion by cells from healthy control subjects (R = 0.603, P = 0.022), but not from CFS patients, and IL-1 beta secretion was not different between groups. Exercise induced a slight (<12%) but significant (P = 0.006) increase in IL-6 secretion, but the responses of the CFS patients were not different than controls. Furthermore, no significant exercise-induced changes in body temperature or plasma alpha(2)-macroglobulin were observed. These data indicate that under basal conditions, CFS is associated with increased IL-6 secretion which is manifested by chronically elevated plasma alpha(2)-macroglabulin concentrations. These modest differences suggest that cytokine dysregulation is not a singular or dominant factor in the pathogenesis of CFS.
引用
收藏
页码:414 / 421
页数:8
相关论文
共 30 条
[1]  
ARNOLD DL, 1984, LANCET, V1, P1367
[2]  
BAROFSKY I, 1991, REV INFECT DIS, V13, pS94
[3]  
BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92
[4]  
Buchwald D, 1997, J RHEUMATOL, V24, P372
[5]   Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome [J].
Cannon, JG ;
Angel, JB ;
Abad, LW ;
Vannier, E ;
Mileno, MD ;
Fagioli, L ;
Wolff, SM ;
Komaroff, AL .
JOURNAL OF CLINICAL IMMUNOLOGY, 1997, 17 (03) :253-261
[6]   Hormonal influences on stress-induced neutrophil mobilization in health and chronic fatigue syndrome [J].
Cannon, JG ;
Angel, JB ;
Abad, LW ;
O'Grady, J ;
Lundgren, N ;
Fagioli, L ;
Komaroff, AL .
JOURNAL OF CLINICAL IMMUNOLOGY, 1998, 18 (04) :291-298
[7]   Menstrual- and gender-dependent variations in circulating IL-1 agonists, antagonists, and binding proteins [J].
Cannon, JG ;
Abad, LW ;
Vannier, E ;
Lynch, EA .
JOURNAL OF LEUKOCYTE BIOLOGY, 1998, 63 (01) :117-123
[8]   ACUTE PHASE RESPONSE IN EXERCISE .2. ASSOCIATIONS BETWEEN VITAMIN-E, CYTOKINES, AND MUSCLE PROTEOLYSIS [J].
CANNON, JG ;
MEYDANI, SN ;
FIELDING, RA ;
FIATARONE, MA ;
MEYDANI, M ;
FARHANGMEHR, M ;
ORENCOLE, SF ;
BLUMBERG, JB ;
EVANS, WJ .
AMERICAN JOURNAL OF PHYSIOLOGY, 1991, 260 (06) :R1235-R1240
[9]  
CANNON JG, 1996, EXERCISE IMMUNE FUNC, P39
[10]   Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancer [J].
Curti, BD ;
Urba, WJ ;
Longo, DL ;
Janik, JE ;
Sharfman, WH ;
Miller, LL ;
Cizza, G ;
Shimizu, M ;
Oppenheim, JJ ;
Alvord, WG ;
Smith, JW .
JOURNAL OF IMMUNOTHERAPY, 1996, 19 (02) :142-148